- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Video: Flemming Ornskov on Shire Strategy
Along with the details of an ambitious new organization restructuring and strategic product plan, Shire CEO Flemming Ornskov emphasizes talks about the importance of alignment with the customer and the untapped potential from Shire’s expertise in that sweet spot in specialty – rare diseases.
Dr. Flemming Ornskov, just ending his first month as the new CEO of Shire – perhaps the most successful stealth company of all, with a track record for periodically recharging its portfolio in pace with emerging areas of real unmet medical need.
Along with the details of an ambitious new organization restructuring and strategic product plan, Ornskov emphasized his background as a physician pediatrician in relating complex science to the real life world of patients and payers, in the commercial marketplace.
The following is a brief excerpt from our conversation, where he talks about the importance of alignment with the customer and the untapped potential from Shire’s expertise in that sweet spot in specialty – rare diseases.
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
